This post was originally published on this site
Eli Lilly & Co. LLY said Wednesday that is capping out-of-pocket insulin costs to $35 for people with commercial health insurance at certain retail pharmacies and it is also lowering the prices of most its insulins, such as pricing non-branded Insulin Lispro at $25 a vial.
The company also plans to cut the list price of Humalog and Humulin in the fourth quarter, though it did not say by how much. Further, Lilly said in April it plans to launch a biosimilar to Lantus, which will cost $92 for a five pack of pens.
“Because…
